Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBI-8000 (tucidinostat) plus nivolumab vs placebo plus nivolumab in unresectable or metastatic melanoma
2019-002521-30Phase 3Active
- Sponsor
- HUYABIO International, LLC
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Tucidinostat + nivolumab with Placebo + nivolumab (2 arms). Primary endpoint: Primary outcome (PFS or similar). Started Nov 2021; status: active.
02
Drugs
tucidinostat
03
Conditions
melanoma
Beyond the preview
Go deeper on 2019-002521-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002521-30.